TNFSF4
ENSG00000117586
Target class
Secreted protein
Chromosome
1
Approved drugs
0
Clinical candidates (approved and in development)
2
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- TNFSF4
- Gene name
- TNF superfamily member 4
- Gene symbol
- TNFSF4
- Previous gene symbols
- TXGP1
- Protein name
- Tumor necrosis factor ligand superfamily member 4 (Glycoprotein Gp34) (OX40 ligand) (OX40L) (TAX transcriptionally-activated glycoprotein 1) (CD antigen CD252)
- OX-40L
- gp34
- CD252
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Tumor necrosis factor superfamily
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 32
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 9.79
- Tissue specificity (Gini)
- 0.43
- Tissue specificity (tau)
- 0.846
- KEGG gene identifiers
- hsa:7292
- Reactome pathways
- R-HSA-5669034
- Protein interaction confidence
- 0.817034
- Protein interaction partners
- 29
- End position
- 173477583
- Start position
- 173162645
- Chromosome
- 1
- Strand
- Reverse
- Membrane
- Single-pass type II membrane protein.
- Nucleoplasm
- Vesicles
- Tissue specificity (tau)
- 0.846243
- Expression inequality (Gini)
- 0.429709
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 9.79
- Cells - Cultured fibroblasts
- 6.49
- Testis
- 5.35
- Esophagus - Gastroesophageal Junction
- 4.16
- Brain - Cerebellar Hemisphere
- 3.7
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes9.79
- Cells - Cultured fibroblasts6.49
- Testis5.35
- Esophagus - Gastroesophageal Junction4.16
- Brain - Cerebellar Hemisphere3.7
- Brain - Cerebellum3.04
- Pituitary3.02
- Esophagus - Muscularis2.64
- Spleen2.44
- Lung2.33
- Prostate2.26
- Cervix - Endocervix1.96
- Fallopian Tube1.86
- Nerve - Tibial1.86
- Cervix - Ectocervix1.8
- Ovary1.72
- Uterus1.62
- Artery - Aorta1.59
- Adrenal Gland1.54
- Vagina1.52
- Bladder1.49
- Colon - Sigmoid1.42
- Artery - Coronary1.36
- Brain - Spinal cord (cervical c-1)1.22
- Adipose - Subcutaneous1.19
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0008284
- GO:0032700
- GO:0032729
- GO:0032753
- GO:0032755
- GO:0050729
- GO:0071222
- GO:0071380
- GO:0005576
- GO:0005886
- GO:0009986
- GO:0005102
- GO:0005515
Related records
Trials (23)
- A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult Participants
- A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
- A PK Comparability Study of Two Different Amlitelimab Drug Products in Healthy Participants
- A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
- A Study of KY1005 in Healthy Volunteers
- A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis
- A Study of RO4989991 in Patients With Allergic Rhinitis
- A Study of Subcutaneous KY1005 in Healthy Volunteers
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
- A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
- An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
- Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
- Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
- Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
- Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Drugs (2)
- Amlitelimab Tumor necrosis factor ligand superfamily member 4 inhibitor
- Oxelumab Tumor necrosis factor ligand superfamily member 4 inhibitor